Scripps MD Anderson (Site 0010)

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Bladder cancer2 trials

Phase

• Phase 32 trials

Status

• Active, not recruiting1 trial
• Completed1 trial

Lead sponsor

• Merck Sharp & Dohme LLC2 trials

Running trials

• Active, not recruiting

  Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

  NCT03924895· Phase 3· Merck Sharp & Dohme LLC· Source

Closed trials

• Completed

  Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

  NCT03924856· Phase 3· Merck Sharp & Dohme LLC· Source